ASTAGRAF XL- tacrolimus extended-release capsules capsule, coated, extended release United States - English - NLM (National Library of Medicine)

astagraf xl- tacrolimus extended-release capsules capsule, coated, extended release

astellas pharma us, inc. - tacrolimus (unii: wm0haq4wnm) (tacrolimus anhydrous - unii:y5l2157c4j) - tacrolimus anhydrous 0.5 mg - astagraf xl® is indicated for the prophylaxis of organ rejection in kidney transplant patients in combination with other immunosuppressants in adult and pediatric patients who can swallow capsules intact [see use in specific populations (8.4) and clinical studies (14.1), (14.2)]. astagraf xl is contraindicated in patients with known hypersensitivity to tacrolimus [see adverse reactions (6.2)] . pregnancy exposure registry there is a pregnancy registry that monitors pregnancy outcomes in women exposed to astagraf xl during pregnancy. the transplantation pregnancy registry international (tpri) is a voluntary pregnancy exposure registry that monitors outcomes of pregnancy in female transplant recipients and those fathered by male transplant recipients exposed to immunosuppressants including tacrolimus. healthcare providers are encouraged to advise their patients to register by contacting the transplantation pregnancy registry international at 1-877-955-6877 or https://www.transplantpregnancyregistry.org/. risk

Advagraf 5mg Prolonged-release hard capsules Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

advagraf 5mg prolonged-release hard capsules

astellas pharma malaysia sdn bhd - tacrolimus -

Advagraf 1mg Prolonged-release hard capsules Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

advagraf 1mg prolonged-release hard capsules

astellas pharma malaysia sdn bhd - tacrolimus -

Advagraf 0.5mg Prolonged-release hard capsules Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

advagraf 0.5mg prolonged-release hard capsules

astellas pharma malaysia sdn bhd - tacrolimus -

PROGRAF CAPSULE 5MG Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

prograf capsule 5mg

astellas pharma malaysia sdn bhd - tacrolimus -

PROGRAF CAPSULE 1MG Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

prograf capsule 1mg

astellas pharma malaysia sdn bhd - tacrolimus -

VESICARE 5 MG FILM-COATED TABLET Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

vesicare 5 mg film-coated tablet

astellas pharma malaysia sdn bhd - solifenacin succinate -

Harnal OCAS 400mcg Film-coated Tablet Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

harnal ocas 400mcg film-coated tablet

astellas pharma malaysia sdn bhd - tamsulosin hydrochloride -

VESICARE 10 MG FILM-COATED TABLET Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

vesicare 10 mg film-coated tablet

astellas pharma malaysia sdn bhd - solifenacin succinate -

PADCEV 20 MG Israel - English - Ministry of Health

padcev 20 mg

astellas pharma international b.v., israel - enfortumab vedotin - powder for concentrate for solution for infusion - enfortumab vedotin 20 mg/vial - enfortumab vedotin - padcev is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer (muc) who: - have previously received a programmed death receptor-1 (pd-1) or programmed death-ligand 1 (pd-l1) inhibitor, and a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting or:- are ineligible for cisplatin-containing chemotherapy and have previously received a pd-1/pd-l1 inhibitor.